Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bayer AG is conducting a clinical study titled An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation. The study aims to explore the safety and efficacy of BAY2927088 in treating advanced NSCLC with specific genetic mutations, which could potentially halt cancer progression.
The intervention being tested is BAY2927088, an oral drug designed to block mutated EGFR and HER2 proteins, potentially stopping the spread of NSCLC. The study seeks to determine the maximum tolerated dose and assess the drug’s movement through the body.
This interventional study is non-randomized with a sequential intervention model and no masking, focusing primarily on treatment. It includes dose escalation, backfill, expansion, and extension parts to evaluate safety and efficacy.
The study began on October 25, 2021, with an active, not recruiting status as of the last update on August 6, 2025. These dates are crucial for tracking progress and anticipating results.
For investors, Bayer’s study could impact stock performance positively if BAY2927088 proves effective, especially given the competitive landscape in cancer treatment. Success could enhance Bayer’s market position, influencing investor sentiment favorably.
The study is ongoing, with further details available on the ClinicalTrials portal.